Metabolic Pathways in *Microbispora* sp. ATCC-PTA 5024, Producer of NAI-107

**Lantibiotic**


*Molecular Microbiology and Biotechnology Laboratory, STEBICEF Department, University of Palermo, Viale delle Scienze, ed. 16, 90128 Palermo.

Proteomic and Mass Spectrometry Laboratory, ISPAAM-CNR, via Argine 1085, 80147 Napoli.

*NAICONS, Via Fantoli 16/15, 20138 Milano.

Interfaculty Institute of Microbiology and Infection Medicine, Eberhard Karls University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen (Germany).

teresa.faddetta@virgilio.it, giuseppe.gallo@unipa.it

Key words: Lantibiotic; Proteomics; Actinomycete

The actinomycete *Microbispora* sp. ATCC-PTA-5024 produces the lantibiotic NAI-107 (1) a promising drug to treat multidrug-resistant pathogen infections (2). *Microbispora* is a poorly characterized and this limited knowledge is detrimental to set-up NAI-107 production processes to efficiently deliver high-quality compound. High throughput techniques, like proteomics, may give insights on strain molecular physiology and biochemical capability and, above all, on metabolic pathways and regulatory mechanisms thereof associated with antibiotic production (3). Thus *Microbispora* differential proteomic analyses were comparatively carried out on wild type, null and super-producer strains by mean of 2-D-Differential Gel Electrophoresis and mass spectrometry procedures. This study revealed differential regulation of pleiotropic regulators, stress response factors and proteins involved in many cell processes and metabolic pathways associated with NAI-107 production on-set and maintenance. In particular, proteins involved in molecular processes like amino sugar, nitrogen, phosphate and sulphur metabolism, oxidative stress and antibiotic biosynthesis and resistance are positively correlated while proteins involved in glycolysis, amino acid and nucleotide metabolism are negatively associated to NAI-107. Therefore, these data coupled to gene ontology, revealed a comprehensive set of differentially regulated proteins which may play roles as trigger or sustaining or response factors in NAI-107 production. Altogether this information may be used as a knowledge background to rationally improve NAI-107 production by *Microbispora* fermentation optimization or for strain improvement by genetic engineering on targeted genes.


Chromatin remodelers, nucleoplasm compartment and proteinopathies

Luca Lo Piccolo, Rosa Bonaccorso, Antonia Maria Rita Ingrassia, Maria Cristina Onorati.

1.Dipartimento STEBICEF, viale delle Scienze ed.16, 90128 Palermo
2. Istituto Telethon Dulbecco c/o Universita’ degli Studi di Palermo, 90128 Palermo

lucalopiccol@gmail.com rosabonaccorsog@gmail.com * mconorati@dti.telethon.it

Keywords: Chromatin remodelers, hnRNPs, proteinopathies

Recent advances in the field of transcriptome exploration have revealed novel sets of new ncRNAs like the long non-coding RNAs, which seem to be key components of epigenetic regulatory networks. Indeed, recent studies have shown that IncRNAs regulate the gene expression by chromatin remodelling, transcription, splicing and RNA decay control, enhancer function, and epigenetic regulation. An emerging theme from multiple model systems is that IncRNAs form extensive networks of ribonucleoprotein (RNP) complexes with numerous chromatin regulators and then target these enzymatic activities to appropriate locations in the genome. Using D. melanogaster as model system, I recently found a functional interaction between ISWI, the catalytic subunit of several ATP-dependent chromatin-remodeling complexes, and the IncRNA hsr-omega (hsrω). In Drosophila the nucleus-limited hsrω-n transcript is dynamically associated with several different